GLOW
Peptide Stack · Combination ConceptRepair, extracellular-matrix, and skin-remodeling research
What Is This Combination?
ERP catalog context: BPC-157 10 mg + TB-500 10 mg + GHK-Cu 50 mg -- total 70 mg
A three-component pairing that builds on BPC-157 and TB-500's repair-research framing and adds GHK-Cu to introduce a copper-peptide, collagen, and extracellular-matrix research arm -- component-level evidence only, with no controlled trial of the exact three-component pairing.
The Concept
GLOW builds on the BPC-157 and TB-500 repair framing and adds GHK-Cu to introduce a copper-peptide, collagen, and extracellular-matrix/skin-remodeling research arm. Grouping these three does not establish that they work better together than any one alone, and GHK-Cu's own evidence is concentrated in a different route of administration (topical) than the systemic injectable use implied by this formulation.
Meet the Components
BPC-157
10 mgtissue-repair and vascular signaling arm
BPC-157 is studied in preclinical models for effects on angiogenesis, tendon and ligament healing, and gastrointestinal mucosal repair.
Evidence base is preclinical (animal/cell) and does not establish human therapeutic efficacy. See the standalone BPC-157 page for its full evidence summary.
Preclinical evidence only
View BPC-157research profile →TB-500
10 mgdistinct cell-migration and remodeling signaling arm
As used on this page, TB-500 refers specifically to the short LKKTETQ fragment derived from thymosin beta-4, not the full-length 43-amino-acid protein.
No FDA-approved TB-500 product exists and FDA reports no identified human exposure data for the exact fragment. See the standalone TB-500 page for its full identity and evidence boundary.
No established human evidence
View TB-500research profile →GHK-Cu
50 mgcopper-peptide extracellular-matrix / collagen-remodeling signaling arm
GHK-Cu is studied for roles in collagen synthesis, extracellular-matrix remodeling, and skin biology, most extensively in topical/cosmetic research contexts -- a different route and research context from BPC-157/TB-500's own literature.
Human evidence is concentrated in topical/cosmetic applications and should not be automatically transferred to systemic injectable use, where route materially changes exposure and relevance. See the standalone GHK-Cu page for its full evidence summary.
Mixed, route-dependent evidence
View GHK-Curesearch profile →How the Roles Fit Together
What the Combination Is Intended to Address
Evidence-Supported Conceptual Domains
- connective-tissue repair
- extracellular matrix biology
- collagen/skin remodeling
- wound/remodeling research
Community-Use Themes
The themes below are editorial summaries of commonly discussed community-use patterns. They are not controlled clinical evidence, systematically sourced community data, or established benefits.
- skin appearance discussions(editorial-summary)
- recovery from training or strains(editorial-summary)
- connective-tissue support discussions(editorial-summary)
- post-procedure recovery discussions(editorial-summary)
Concerns & Evidence Gaps
Safety Consideration
No controlled three-component clinical validation exists.Safety Consideration
GHK-Cu's evidence base is concentrated in topical/cosmetic use; systemic injectable exposure is a different route/context not established by that literature.Safety Consideration
Copper exposure from GHK-Cu is fixed into the blend and cannot be adjusted independently.Safety Consideration
The three components have different pharmacokinetic profiles and tissue targets, which complicates predicting a combined effect.Safety Consideration
A fixed blend makes it impossible to isolate which component, if any, is the source of an observed response.Safety Consideration
TB-500 as sold is a short fragment distinct from full-length thymosin beta-4; findings for the full-length protein cannot be assumed to apply.
Why Separate Components May Sometimes Be Preferable
Presented as a scientific/practical tradeoff, not a recommendation.
Favoring Separate Administration
- GHK-Cu's own evidence is largely topical, so pairing it with two systemically-dosed components changes its research context in a way that has not itself been studied.
- Three independently-developing evidence bases are harder to reason about together than one at a time.
- Separate administration allows any one component to be discontinued without affecting the other two.
- The fixed 10 mg / 10 mg / 50 mg ratio is a supplier convention, not a pharmacologically validated ratio.
Favoring the Fixed-Ratio Blend
- A single 70 mg fixed blend is more convenient to source and administer than three separate vials and schedules.
Convenience is not evidence of biological superiority.
Evidence Boundary
The components of this combination have been investigated individually to varying degrees. Evidence for an individual component does not automatically establish the safety, efficacy, compatibility, or synergy of the exact combination. Where direct combination studies exist, MitoCore identifies that explicitly. Where they do not, the page describes the biological rationale for the combination rather than presenting the stack itself as a validated therapeutic intervention.
Exact-combination status: No controlled or observational human trial of the exact three-component GLOW combination was located. What exists is separate research on each component individually, much of it in different research contexts (systemic/preclinical for BPC-157 and TB-500, largely topical for GHK-Cu).
Limitations: Component-level findings, especially GHK-Cu's largely topical evidence base, do not establish the combined systemic injectable formulation's safety, efficacy, or an evidence-derived mixing ratio.
Component evidence: Evidence strength varies by component and, for GHK-Cu, by route of administration -- see each component's own standalone page for its full evidence summary.
Explore the Components
Each component's full evidence base lives on its own standalone research profile.
BPC-157
BPC-157 is an experimental 15-amino-acid peptide promoted for repair and gastrointestinal uses. Published human evidence consists of two tiny uncontrolled pilots and one retrospective private-clinic report; most mechanistic support remains preclinical. FDA has identified significant product-characterization, impurity, aggregation, immunogenicity, and long-term safety uncertainties.
View research profile →TB-500
TB-500 is marketed as the short thymosin-beta-4 fragment LKKTETQ and is not the same molecule as full-length 43-amino-acid thymosin beta-4. FDA reports no identified human exposure data for drug products containing the exact fragment. Human studies of full-length thymosin beta-4 and RGN-259 are related biological context only and do not establish TB-500 efficacy, safety, pharmacokinetics, or dosing.
View research profile →GHK-Cu
GHK-Cu is the copper(II) complex of the tripeptide GHK. Research includes cell, animal, formulation, biomaterial, and limited topical human studies. The available topical human evidence does not establish broad anti-aging, hair-growth, or wound-treatment efficacy, and it cannot support systemic injectable claims. FDA separately identifies aggregation, peptide-impurity, immunogenicity, and limited-human-data concerns for compounded injectable GHK-Cu.
View research profile →Disclaimer
See the anecdotal notice above for community-discussion context.
This page does not establish combination efficacy, safety, or compatibility beyond what is explicitly cited above. Always review each component's own standalone research profile for its full evidence base.